1 Department of Radiology, Duke University Medical Center, DUMC Box 3808, Durham, NC 27710.
AJR Am J Roentgenol. 2015 May;204(5):W579-85. doi: 10.2214/AJR.14.13278.
The purpose of this study is to measure the organ doses and effective dose (ED) for parathyroid 4D CT and scintigraphy and to estimate the lifetime attributable risk of cancer incidence associated with imaging.
Organ radiation doses for 4D CT and scintigraphy were measured on the basis of imaging with our institution's protocols. An anthropomorphic phantom with metal oxide semiconductor field effect transistor detectors was scanned to measure CT organ dose. Organ doses from the radionuclide were based on International Commission for Radiological Protection report 80. ED was calculated for 4D CT and scintigraphy and was used to estimate the lifetime attributable risk of cancer incidence for patients differing in age and sex with the approach established by the Biologic Effects of Ionizing Radiation VII report. A 55-year-old woman was selected as the standard patient according to the demographics of patients with primary hyperparathyroidism.
Organs receiving the highest radiation dose from 4D CT were the thyroid (150.6 mGy) and salivary glands (137.8 mGy). For scintigraphy, the highest organ doses were to the colon (41.5 mGy), gallbladder (39.8 mGy), and kidneys (32.3 mGy). The ED was 28 mSv for 4D CT, compared with 12 mSv for scintigraphy. In the exposed standard patient, the lifetime attributable risk for cancer incidence was 193 cancers/100,000 patients for 4D CT and 68 cancers/100,000 patients for scintigraphy. Given a baseline lifetime incidence of cancer of 46,300 cancers/100,000 patients, imaging results in an increase in lifetime incidence of cancer over baseline of 0.52% for 4D CT and 0.19% for scintigraphy.
The ED of 4D CT is more than double that of scintigraphy, but both studies cause negligible increases in lifetime risk of cancer. Clinicians should not allow concern for radiation-induced cancer to influence decisions regarding workup in older patients.
本研究旨在测量甲状旁腺 4D CT 和闪烁扫描的器官剂量和有效剂量(ED),并估计与成像相关的癌症发病的归因终生风险。
根据我们机构的方案进行成像,测量 4D CT 和闪烁扫描的器官辐射剂量。使用带有金属氧化物半导体场效应晶体管探测器的人体模型进行扫描,以测量 CT 器官剂量。放射性核素的器官剂量基于国际辐射防护委员会报告 80。计算 4D CT 和闪烁扫描的 ED,并使用第七版《电离辐射生物效应》报告中建立的方法,根据年龄和性别不同的患者来估计癌症发病的归因终生风险。选择一名 55 岁女性作为标准患者,其人口统计学特征符合原发性甲状旁腺功能亢进患者。
4D CT 中接受最高辐射剂量的器官是甲状腺(150.6 mGy)和唾液腺(137.8 mGy)。对于闪烁扫描,最高的器官剂量是结肠(41.5 mGy)、胆囊(39.8 mGy)和肾脏(32.3 mGy)。4D CT 的 ED 为 28 mSv,而闪烁扫描为 12 mSv。在暴露的标准患者中,4D CT 的癌症发病归因终生风险为 193 例/10 万患者,而闪烁扫描为 68 例/10 万患者。假设癌症的基线终生发病率为 46300 例/10 万患者,成像导致基线癌症终生发病率增加 0.52%,4D CT 为 0.19%,闪烁扫描为 0.19%。
4D CT 的 ED 是闪烁扫描的两倍多,但这两种研究都导致癌症发病的终生风险增加可忽略不计。临床医生不应该因为担心辐射致癌而影响对老年患者的检查决策。